To obtain a new recombinant adenovirus vector having a self copying function in vivo still after partially losing its E1 domain, but not capable of forming infectious adenovirus particles and suitable for a gene transfer in systemic gene therapy.

This new recombinant adenovirus vector having a self copying function in vivo after losing partially its E1 domain, but not capable of forming infectious adenovirus particles, has an increased stability in vivo and is suitable for a gene transfer in a systemic gene therapy, and it is possible to perform a long time therapy of gene insufficient patients with the vector having a transgenic DNA sequence to a lost gene. The recombinant adenovirus vector is obtained by eliminating partially the E1 domain from the recombinant, and leaving a single chain DNA-binding protein DBT, an adenovirus DNA polymerase and a terminal protein pTP gene from the adenovirus behind without eliminating them.